Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation

Nature Chemical Biology

Volumn 11, Issue 5, 2015, Pages 339-346

  Li, Li ^a   Liu, Yuan ^a   Chen, Hang Zi ^a   Li, Feng Wei ^a   Wu, Jian Feng ^a   Zhang, Hong Kui ^a   He, Jian Ping ^a   Xing, Yong Zhen ^a   Chen, Yan ^a   Wang, Wei Jia ^a   Tian, Xu Yang ^a   Li, An Zhong ^a   Zhang, Qian ^a   Huang, Pei Qiang ^a   Han, Jiahuai ^a   Lin, Tianwei ^a   Wu, Qiao ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; N-PENTYL 2-(3,5-DIHYDROXY-2-(1-NONANOYL)PHENYL)ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; NR4A1 PROTEIN, MOUSE; NUCLEAR RECEPTOR NUR77; PHENYLACETIC ACID DERIVATIVE; TRANSCRIPTION FACTOR RELA;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; COMPLICATION; CONFORMATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HOMEOSTASIS; INFLAMMATION; KNOCKOUT MOUSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; SEPSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; HOMEOSTASIS; INFLAMMATION; LIGANDS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENYLACETATES; SEPSIS; TRANSCRIPTION FACTOR RELA;

EID: 84932186336     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1788     Document Type: Article

References (58)

1. Lever, A. & Mackenzie, I. Sepsis: definition, epidemiology, and diagnosis. Br. Med. J. 335, 879-883 (2007).
2. Hartman, M.E., LindeZwirble, W.T., Angus, D.C. & Watson, R.S. Trends in the epidemiology of pediatric severe sepsis. Pediatr. Crit. Care Med. 14, 686-693 (2013).
3. Ulloa, L. & Tracey, K.J. The "cytokine profile": a code for sepsis. Trends Mol. Med. 11, 56-63 (2005).
4. Beutler, B. & Rietschel, E.T. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3, 169-176 (2003).
5. Akira, S. & Takeda, K. Tolllike receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
6. Han, J. & Ulevitch, R.J. Limiting inflammatory responses during activation of innate immunity. Nat. Immunol. 6, 1198-1205 (2005).
7. Hayden, M.S. & Ghosh, S. Signaling to NF-?B. Genes Dev. 18, 2195-2224 (2004).
8. Beyaert, R. et al. The p38/RK mitogenactivated protein kinase pathway regulates interleukin6 synthesis response to tumor necrosis factor. EMBO J. 15, 1914-1923 (1996).
9. Vanden Berghe, W. et al. p38 and extracellular signalregulated kinase mitogenactivated protein kinase pathways are required for nuclear factorB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273, 3285-3290 (1998).
10. Ono, K. & Han, J. The p38 signal transduction pathway: activation and function. Cell. Signal. 12, 1-13 (2000).
11. Saha, R.N., Jana, M. & Pahan, K. MAPK p38 regulates transcriptional activity of NF-?B in primary human astrocytes via acetylation of p65. J. Immunol. 179, 7101-7109 (2007).
12. Hazel, T.G., Nathans, D. & Lau, L.F. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc. Natl. Acad. Sci. USA 85, 8444-8448 (1988).
13. Pei, L., Castrillo, A., Chen, M., Hoffmann, A. & Tontonoz, P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J. Biol. Chem. 280, 29256-29262 (2005).
14. Bonta, P.I. et al. Nuclear receptors Nur77, Nurr1, and NOR1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler. Thromb. Vasc. Biol. 26, 2288-2294 (2006).
15. You, B., Jiang, Y.Y., Chen, S., Yan, G. & Sun, J. The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of I?B? expression. Circ. Res. 104, 742-749 (2009).
16. Hamers, A.A. et al. Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis. Circ. Res. 110, 428-438 (2012); erratum 110, e46 (2012).
17. Hanna, R.N. et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ. Res. 110, 416-427 (2012).
18. Doi, K., Leelahavanichkul, A., Yuen, P.S. & Star, R.A. Animal models of sepsis and sepsis-induced kidney injury. J. Clin. Invest. 119, 2868-2878 (2009).
19. Litvak, V. et al. Function of C/EBP? in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat. Immunol. 10, 437-443 (2009).
20. Tian, B., Nowak, D.E., Jamaluddin, M., Wang, S. & Brasier, A.R. Identification of direct genomic targets downstream of the nuclear factor-?B transcription factor mediating tumor necrosis factor signaling. J. Biol. Chem. 280, 17435-17448 (2005).
21. Németh, Z.H. et al. cDNA microarray analysis reveals a nuclear factor-?B-independent regulation of macrophage function by adenosine. J. Pharmacol. Exp. Ther. 306, 1042-1049 (2003).
22. Wang, H. et al. NF-?B regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell. Biol. 27, 4374-4387 (2007).
23. Alkalay, I. et al. Stimulation-dependent I?B? phosphorylation marks the NF-?B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 92, 10599-10603 (1995).
24. Hong, C.Y. et al. Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor ?. Mol. Cell. Biol. 24, 2593-2604 (2004).
25. Zhan, Y.Y. et al. The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nat. Chem. Biol. 8, 897-904 (2012).
26. Kang, Y.J. et al. Macrophage deletion of p38? partially impairs lipopolysaccharide-induced cellular activation. J. Immunol. 180, 5075-5082 (2008).
27. Malek, S., Huxford, T. & Ghosh, G. I?B? functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-?B. J. Biol. Chem. 273, 25427-25435 (1998).
28. Sun, S.C., Ganchi, P.A., Ballard, D.W. & Greene, W.C. NF-?B controls expression of inhibitor I?B?: evidence for an inducible autoregulatory pathway. Science 259, 1912-1915 (1993).
29. Arenzana-Seisdedos, F. et al. Nuclear localization of I?B? promotes active transport of NF-?B from the nucleus to the cytoplasm. J. Cell Sci. 110, 369-378 (1997).
30. Han, J., Lee, J.D., Bibbs, L. & Ulevitch, R.J.A. MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811 (1994).
31. Trempolec, N., Dave-Coll, N. & Nebreda, A.R. SnapShot: p38 MAPK substrates. Cell 152, 924-924 e1 (2013).
32. Liu, B. et al. Regulation of the orphan receptor TR3 nuclear functions by c-Jun N terminal kinase phosphorylation. Endocrinology 148, 34-44 (2007).
33. Wang, A., Rud, J., Olson, C.M. Jr., Anguita, J. & Osborne, B.A. Phosphorylation of Nur77 by the MEK-ERK-RSK cascade induces mitochondrial translocation and apoptosis in T cells. J. Immunol. 183, 3268-3277 (2009).
34. Chen, H.Z. et al. The orphan receptor TR3 suppresses intestinal tumorigenesis in mice by downregulating Wnt signalling. Gut 61, 714-724 (2012).
35. Liu, J.J. et al. A unique pharmacophore for activation of the nuclear orphan receptor Nur77 in vivo and in vitro. Cancer Res. 70, 3628-3637 (2010).
36. Wang, W.J. et al. Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway. Nat. Chem. Biol. 10, 133-140 (2014).
37. Dogné, J.M., Supuran, C.T. & Pratico, D. Adverse cardiovascular effects of the coxibs. J. Med. Chem. 48, 2251-2257 (2005).
38. Mukherjee, D., Nissen, S.E. & Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. J. Am. Med. Assoc. 286, 954-959 (2001).
39. Dinarello, C.A. Anti-inflammatory agents: present and future. Cell 140, 935-950 (2010).
40. Peifer, C., Wagner, G. & Laufer, S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 6, 113-149 (2006).
41. Hynes, J. Jr. & Leftheri, K. Small molecule p38 inhibitors: novel structural features and advances from 2002-2005. Curr. Top. Med. Chem. 5, 967-985 (2005).
42. Pettus, L.H. & Wurz, R.P. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008. Curr. Top. Med. Chem. 8, 1452-1467 (2008).
43. Genovese, M.C. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 60, 317-320 (2009).
44. Zhang, J., Shen, B. & Lin, A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol. Sci. 28, 286-295 (2007).
45. Goldstein, D.M. & Gabriel, T. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr. Top. Med. Chem. 5, 1017-1029 (2005).
46. Davidson, W. et al. Discovery and characterization of a substrate selective p38?inhibitor. Biochemistry 43, 11658-11671 (2004).
47. Subramanian, A. et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genomewide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
48. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
49. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
50. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
51. Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011).
52. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximumlikelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
53. Cogan, U., Kopelman, M., Mokady, S. & Shinitzky, M. Binding affinities of retinol and related compounds to retinol binding proteins. Eur. J. Biochem. 65, 71-78 (1976).
54. Chen, R., Li, L. & Weng, Z. ZDOCK: an initialstage proteindocking algorithm. Proteins 52, 80-87 (2003).
55. Li, L., Chen, R. & Weng, Z. RDOCK: refinement of rigidbody protein docking predictions. Proteins 53, 693-707 (2003).
56. Brooks, B.R. et al. Charmm-A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4, 187-217 (1983).
57. Banks, J.L. et al. Integrated modeling program, applied chemical theory (IMPACT). J. Comput. Chem. 26, 1752-1780 (2005).
58. Shivakumar, D. et al. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J. Chem. Theory Comput. 6, 1509-1519 (2010).